Rate of conversion and recurrence after sotalol treatment in patients with direct current-refractory atrial fibrillation

Clinical Cardiology

Volumn 29, Issue 2, 2006, Pages 56-60

  Nergårdh, Anna ^a   Nordlander, Rolf ^a   Frick, Mats ^a  

^a STOCKHOLM SÖDER HOSPITAL   (Sweden)

Author keywords

Arrhythmias; Atrial fibrillation; Cardioversion; Sotalol

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DILTIAZEM; SOTALOL;

ADULT; AGED; ARTICLE; BODYWORK; CARDIOVERSION; CONTROLLED STUDY; DIRECT CURRENT; DIZZINESS; DRUG EFFECT; DRUG EFFICACY; DYSPNEA; ELECTROCARDIOGRAPHY; FATIGUE; FEMALE; HEART ATRIUM FIBRILLATION; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; PROSPECTIVE STUDY; RECURRENT DISEASE; SINUS RHYTHM; TACHYCARDIA; TREATMENT FAILURE;

EID: 32544444614     PISSN: 01609289     EISSN: None     Source Type: Journal    
DOI: 10.1002/clc.4960290204     Document Type: Article

References (21)

1. Kannel WB, Abbot RD, Savage DD, Mc Namara PM: Epidemiological features of chronic atrial fibrillation: The Framingham study. N Engl J Med 1982;306:1018-1022
2. Van Gelder IC, Crijns HJ, Van Gilst WH, Verwer R, Lie KI: Prediction of uneventful cardioversion and maintenance of sinus rhythm from direct-current electrical cardioversion of chronic atrial fibrillation. Am J Cardiol 1991; 68:41-46
3. Page RL, Kerber RE, Russell JK, Trouton T, Waktare J, Gallik D, Olgin JE, Ricard P, Dalzell GW, Reddy R, Lazzara R, Lee K, Carlson M, Halperin B, Bardy GH: Biphasic versus monophasic shock waveform for conversion of atrial fibrillation: The results of an international randomized, double-blind multicenter trial. J Am Coll Cardiol 2002;39:1956-1963
4. Taramasco V, Socas A, Ricard P, Levy S: Internal low-energy cardioversion: A therapeutic option for restoring sinus rhythm in chronic atrial fibrillation after failure of external cardioversion. Europace 1999;1:179-182
5. Li H, Natale A, Tomassoni G, Beheiry S, Cooper P, Leonelli F, Easley A, Barrington W, Windle J: Usefulness of ibutilide in facilitating successful external cardioversion of refractory atrial fibrillation. Am J Cardiol 1999;84: 1096-1098
6. Van Noord T, Van Gelder I, Schoonderwoerd B, Crijns HJ: Immediate reinitiation of atrial fibrillation after electrical cardioversion predicts subsequent pharmacologic and electrical conversion to sinus rhythm on amiodarone. Am J Cardiol 2000;86:1384-1385
7. Wang M, Dorian P: DL and D sotalol decrease defibrillation energy require-ments. PACE Pacing Clin Electrophysiol 1989;12:1522-1529
8. Dorian P, Newman D: Effect of sotalol on ventricular fibrillation and defibrillation in humans. Am J Cardiol 1993;72:72A-79A
9. Henry WL, Morganroth J, Pearlman AS, Clark CE, Redwood DR, Itscoitz SB, Epstein SE: Relation between echocardiographically determined left atrial size and atrial fibrillation. Circulation 1976;53:273-279
10. Dittrich HC, Erickson JS, Schneiderman T, Blacky AR, Savides T, Nicod PH: Echocardiographic and clinical predictors for outcome of elective cardioversion of atrial fibrillation. Am J Cardiol 1989;63:193-197
11. Carlsson J, Tebbe U, Rox J, Harmjanz D, Haerten K, Neuhaus KL, Seidel F, Niederer W, Miketic S: ALKK-study group: Cardioversion of atrial fibrillation in elderly. Am J Cardiol 1996;78:1380-1384
12. Frick M, Frykman V, Jensen-Urstad M, Ostergren J, Rosenqvist M: Factors predicting success rate and recurrence of atrial fibrillation after first electrical cardioversion in patients with persistent atrial fibrillation. Clin Cardiol 2001;24(3):238-244
13. Kerber RE, Grayzel J, Hoyt R, Marcus M, Kennedy J: Transthoracic resistance in human defibrillation. Influence of body weight, chest size, serial shocks, paddle size and paddle contact pressure. Circulation 1981;63: 676-682
14. Sopher SM, Murgatroyd FDM, Slade AKB, Blankoff I, Rowland E, Ward DE, Camm AJ: Low energy transvenous cardioversion of atrial fibrillation resistant to transthoracic shocks. Br Heart J 1996;75:635-638
15. Van Gelder I, Crijins HJGM, van Gilst WH, de Langen CDI, van Wijik LM, Lie KI: Effects of flecainide on the atrial defibrillation threshold. Am J Cardiol 1989;63:112-114
16. Boriani G, Biffi M, Capucci A, Bronzetti G, Ayers GM, Zannoli R, Branzi A, Magnani B: Favorable effects of flecainide in transvenous internal cardioversion of atrial fibrillation. J Am Coll Cardiol 1999;33:333-341
17. Bianconi L, Mennuni M, Lukic V, Castro A, Chieffi M, Santini M: Effects of oral propafenone administration before electrical cardioversion of chronic atrial fibrillation. A placebo-controlled study. J Am Coll Cardiol 1996;28: 700-706
18. Lai L, Lin I, Lien W, Tseng YZ, Huang SK: Intravenous sotalol decreases transthoracic cardioversion energy requirement for chronic atrial fibrillation in humans. J Am Coll Cardiol 2000;35:1434-1441
19. Frick M, Darpö B, Östergren J, Rosenqvist M: The effect of oral magnesium, alone or as an adjuvant to sotalol, after cardioversion in patients with persistent atrial fibrillation. Eur Heart J 2000;21:1177-1185]
20. Hohnloser SH, Van de Loo A, Baedecker F: Efficacy and proarrhythmic hazards of pharamocologic cardioverison of atrial fibrillation: Prospective comparison of sotalol versus quinidine. J Am Coll Cardiol 1995;26:852-858
21. Juul-Möller S, Edvardsson N, Rehnqvist-Ahlberg N: Sotalol versus quinidine for the maintenance of sinus rhythm after direct current conversion of atrial fibrillation. Circulation 1990;82:1932-1939